Skip to main content
Premium Trial:

Request an Annual Quote

Oracle Joins WIN Consortium

NEW YORK (GenomeWeb News) – The Worldwide Innovative Network (WIN) in personalized cancer medicine consortium announced today that Oracle Health Sciences has joined the consortium.

Oracle will provide access to its data management, clinical trials, genomics, and analytics expertise to WIN. The software giant has developed integrated, cloud-based applications that allow new collaboration models between research organizations and healthcare organizations, and its participation in WIN is anticipated to accelerate translational research, healthcare analytics, and health information exchange "by allowing these organizations to more efficiently share and analyze de-identified data across organizational boundaries," Oracle said.

John Mendelsohn, chairman of WIN Consortium and past president of the University of Texas MD Anderson Cancer Center, said that collaboration among health science researchers is essential, but technological obstacles have made such partnerships difficult.

"Oracle is helping organizations to break down these barriers and lay a foundation for expanded collaboration and new insight," he said in a statement.

"Our overarching goals are to achieve groundbreaking personalized cancer medicine discoveries and to significantly improve the outcomes and quality of life for cancer patients," Alexander Eggermont, general director of Institut Gustave Roussy and vice-chairman of WIN Consortium, added. "With the dropping cost of whole genome sequencing, technology is essential to helping us analyze this rich data and achieve our goals."

WIN Consortium comprises 24 academic institutions and industries and seeks to improve cancer diagnostics and therapies.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.